Sorrento Therapeutics (NASDAQ:SRNE) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

NASDAQ:SRNE opened at $0.02 on Tuesday. Sorrento Therapeutics has a one year low of $0.00 and a one year high of $0.42. The firm’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.05.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.